Publikationen von Thomas Zander
Alle Typen
Zeitschriftenartikel (27)
2015
Zeitschriftenartikel
16, 7 (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology 2014
Zeitschriftenartikel
4 (4), S. 415 - 422 (2014)
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery
Zeitschriftenartikel
4 (2), S. 246 - 257 (2014)
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery 2013
Zeitschriftenartikel
8 (1), e53081 (2013)
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with Erlotinib. PLoS ONE
Zeitschriftenartikel
5 (209), 209ra153 (2013)
A genomics-based classification of human lung tumors. Science Translational Medicine 2012
Zeitschriftenartikel
150 (6), S. 1107 - 1120 (2012)
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell
Zeitschriftenartikel
37 (11), S. 1058 - 1064 (2012)
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clinical Nuclear Medicine
Zeitschriftenartikel
39 (7), S. 1117 - 1127 (2012)
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging
Zeitschriftenartikel
44 (10), S. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics
Zeitschriftenartikel
77 (3), S. 617 - 620 (2012)
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. Lung Cancer
Zeitschriftenartikel
137 (42), S. 2179 - 2180 (2012)
Personalisierte Therapie von Lungenkrebs. Deutsche Medizinische Wochenschrift 2011
Zeitschriftenartikel
1 (1), S. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Zeitschriftenartikel
52 (12), S. 1 - 7 (2011)
Quantitative analysis of response to treatment with Erlotinib in advanced non–small cell lung cancer using 18F-FDG and 39-deoxy-39-18F-fluorothymidine PET. Journal of Nuclear Medicine
Zeitschriftenartikel
6 (5), S. e19601 - e19601 (2011)
Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS ONE
Zeitschriftenartikel
17 (10), S. 3360 - 3367 (2011)
Blood-based gene expression signatures in non-small cell lung cancer. Clinical Cancer Research
Zeitschriftenartikel
29 (13), S. 1701 - 1708 (2011)
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 2010
Zeitschriftenartikel
5 (3), S. 407 - 409 (2010)
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR mutations and bone metastases during treatment with EGFR kinase inhibitors. Journal of Thoracic Oncology
Zeitschriftenartikel
2 (62), S. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2009
Zeitschriftenartikel
106, S. 18351 - 18356 (2009)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America
Zeitschriftenartikel
119 (6), S. 1727 - 1740 (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. Journal of Clinical Investigation